When was OncoC4 founded?

OncoC4 was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is OncoC4 located?

OncoC4 is headquartered in Rockville, United States.

Who is the current CEO of OncoC4?

Yang Liu of OncoC4. They have also founded 1 company.

How many employees does OncoC4 have?

As of Feb 28, 2026, the latest employee count at OncoC4 is 70.

Is OncoC4 a funded company?

OncoC4 is a funded company, having raised a total of $50M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 03, 2020.

When was the latest funding round of OncoC4?

OncoC4's latest funding was a $***** Series B round on Oct 02, 2025, with participation from 3 investors.

Where does OncoC4 rank among its competitors?

OncoC4 ranks 421st amongst 3350 active competitors, of which 1137 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was OncoC4, which secured $50M in Oct, 2025.

Who are the top competitors of OncoC4?

OncoC4's top competitors include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Among them, OncoC4 secured the most recent funding round in October, 2025.

OncoC4 - 2026 Company Profile, Team, Funding & Competitors

OncoC4 is a series B company based in Rockville (United States), founded in 2020 by Yang Liu. It operates as a Developer of immunotherapy for cancer patients. OncoC4 has raised $50M in funding from GBA Fund. The company has 3350 active competitors, including 1137 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications.

Company Details

Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.

Website: oncoc4.com/en/
Email ID: *****@oncoc4.com

Key Metrics

Founded Year

2020

Location

Rockville, United States

Stage

Series B

Total Funding

$50M in 2 rounds

Latest Funding Round

Series B, Oct 02, 2025, $*****

Investors

GBA Fund & 5 more

Ranked

421^st among 3350 active competitors

Employee Count

70 as on Feb 28, 2026

Similar Companies

Jazz Pharmaceuticals & 3175 more

View OncoC4's full profile

OncoC4 has raised a total funding of $50M over 2 rounds. Its first funding round was on Apr 03, 2020. Its latest funding round was a Series B round on Oct 02, 2025 for $*****. 3 investors participated in its latest round. OncoC4 has 6 institutional investors.

Here is the list of recent funding rounds of OncoC4:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 02, 2025	1733635	Series B	7183799	2965218	8135913	7231143
Apr 03, 2020	9833779	Grant (prize money)	8454421	7227470	5307456	HHS

Access funding benchmarks and valuations. Sign up today!

View details of OncoC4's funding rounds and investors

The founders of OncoC4 is Yang Liu.

Here are the details of OncoC4's key team members:

Yang Liu: Co-Founder & CEO of OncoC4.
Contact Info: 1 email address

View details of OncoC4's Founder profiles and Board Members

OncoC4's employee count trend

OncoC4 has 70 employees as of Feb 26. Here is OncoC4's employee count trend over the years:

Uncover OncoC4's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OncoC4 include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Here is the list of Top 10 competitors of OncoC4, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Vivo Capital & 10 others	79/100
3rd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, Tamburi Investment Partners ... & 4 others	78/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Baillie Gifford & 17 others	75/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of drugs based on T-Cell receptor technology for the treatment of cancer	$601M	BlackRock, General Atlantic & 50 others	74/100
8th	FibroGen 1993, San Francisco (United States), Public	Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.	$215M	Adage Capital Management, Corriente Biotechnology Partners ... & 26 others	72/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
421st	OncoC4 2020, Rockville (United States), Series B	Developer of immunotherapy for cancer patients	$50M	HM Capital, Kaitai Capital Management & 4 others	56/100